Delivery Order SPE2DB22D1002-SPE2DB25FLHG6
- Not listed
- The Defense Logistics Agency awarded a $1,944.90 delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL vials (10 mL) on July 18, 2025, with completion scheduled for July 21, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical federal vendor specializing in medical supply chain support for military and veteran healthcare...
- The Defense Logistics Agency awarded a delivery order valued at $5,186.40 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL vials (10mL) on September 16, 2025, with completion scheduled for September 17, 2025. This firm fixed-price delivery order was awarded without set-aside designation through competitive procurement. The pharmaceutical product will be delivered to AmerisourceBergen's corporate headquarters location in Conshohocken, Pennsylvania, supporting the agency's medical supply...
- The Defense Logistics Agency awarded a delivery order valued at $2,372.92 to AmerisourceBergen Drug Corp for the supply of NovoLog 100 Unit/mL vials (10 mL) on June 18, 2025, with an ultimate completion date of June 20, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded through open procurement. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of NovoLog 100 Unit/mL vials (10 mL) with a ceiling value of $1,424.55. This competitive award, issued under a firm fixed-price delivery order contract type, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. The order does not utilize a...
- The Defense Logistics Agency awarded a delivery order valued at $4,819.02 to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of NovoLog 100 Unit/mL vials (10 mL). The contract, classified as a firm fixed price delivery order with an ultimate completion date of August 18, 2025, will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This award was made through open competition with no set-aside designation. This delivery order is issued...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,761.94 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL vials (10mL) on June 16, 2025, with an ultimate completion date of June 17, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a $3,362.46 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of NovoLog 100 Unit/mL vials (10mL), with an ultimate completion date of September 19, 2025. This contract was competitively awarded without set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves...
- The Defense Logistics Agency awarded a $2,443.49 firm fixed-price delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL vials (10 mL) on July 14, 2025, with an ultimate completion date of July 15, 2025. This is a non-set-aside contract representing a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999.99 billion through December 2026. The product will be performed at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of NovoLog 100 Unit/mL vials (10mL) with a ceiling value of $1,619.42. This firm fixed-price delivery order is non-competitive and represents a child award under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.9 billion through December 2026. The pharmaceutical distributor, headquartered in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a delivery order valued at $1,383.81 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL vials (10mL) on August 5, 2025, with an ultimate completion date of August 6, 2025. This firm fixed price delivery order was awarded without set-aside designation through open competition and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical supply transaction supporting...
- SPE2DB22D1002Indefinite Delivery Contract
- SPE2DB22D1002-SPE2DB25FLHG6Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $8,924.09 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL vials (10 mL) on September 5, 2025, with an ultimate completion date of September 8, 2025. This is a firm fixed-price, non-set-aside contract executed under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 global pharmaceutical support vehicle running through December 2026. The delivery order will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania location, where the company maintains its corporate headquarters and operates as a major pharmaceutical distributor for federal medical procurement. This delivery order represents a routine pharmaceutical supply transaction within AmerisourceBergen's extensive portfolio of federal medical products. The company serves as a critical vendor for military and veteran healthcare systems through the DLA's Pharmaceutical Prime Vendor program, supplying a comprehensive range of brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains. The NovoLog insulin product supports diabetes management needs within the Defense Health Agency and other federal healthcare systems. The non-set-aside award reflects the company's demonstrated capability to meet federal procurement requirements through open competition, consistent with the company's track record of competitively awarded delivery orders ranging from nominal to substantial values.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.9k | 9/5/25 |